



Sunil Arani Reddy

Clinical Associate Professor, Medicine - Oncology

CLINICAL OFFICE (PRIMARY)

- **Stanford Cancer Center**

875 Blake Wilbur Dr Rm CC2232

MC 6501

Stanford, CA 94305

Tel (650) 736-1234 Fax (650) 736-1373

Bio

CLINICAL FOCUS

- Cancer > Cutaneous (Dermatologic) Oncology
- lymphoma/melanoma/cutaneouslymphoma
- Medical Oncology

ACADEMIC APPOINTMENTS

- Clinical Associate Professor, Medicine - Oncology
- Member, Stanford Cancer Institute

PROFESSIONAL EDUCATION

- Medical Education: University of California at Irvine School of Medicine (1994) CA
- Board Certification: Medical Oncology, American Board of Internal Medicine (2015)
- Fellowship: Stanford University Hematology and Oncology Fellowship (2000) CA
- Residency: University of Michigan Health System Internal Medicine Residency (1997) MI
- Internship: University of Michigan Health System Internal Medicine Residency (1995) MI

LINKS

- Get a Second Opinion: <https://stanfordhealthcare.org/second-opinion/overview.html>

Research & Scholarship

CLINICAL TRIALS

- ACTengine® IMA203 vs. investigator's choice in previously treated, unresectable or metastatic cutane, Recruiting
- Phase II Adjuvant Nivolumab With or Without Cabozantinib in Resected Mucosal Melanoma, Recruiting
- A Phase II Autologous Tumor-infiltrating Lymphocytes (TILs) in Advanced Melanoma, Not Recruiting

- A Study of Bevacizumab With Carboplatin and Paclitaxel Chemotherapy for the First-Line Treatment of Patients With Metastatic Melanoma, Not Recruiting
- Expanded Access Ipilimumab (BMS-734016) Monotherapy in Unresectable Stage III or Stage IV Melanoma, Not Recruiting
- Melphalan/HDS Treatment in Hepatic-Dominant Ocular Melanoma, Not Recruiting
- Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma, Not Recruiting
- Open-Label Expanded Access Melphalan/Hepatic Delivery System(HDS) in HepaticDominant Ocular Melanoma, Not Recruiting
- Phase I Atezolizumab (MPDL3280A) IV - Single Agent in Locally Advanced or Metastatic Solid Tumors, Not Recruiting
- Phase I Ipilimumab & Nivolumab (Blockade) + External Beam Radiotherapy in Stage IV Melanoma, Not Recruiting
- Phase I MGD009 in Unresectable /Metastatic B7-H3-Expressing Neoplasms, Not Recruiting
- Phase I MRG-106 After Local Intratumoral+Subcutaneous+IV Administration in Lymphomas & Leukemias, Not Recruiting
- Phase I TRK Inhibitor Selitrectinib-BAY 2731954 in Adult & Pediatric PreviouslyTx NTRK FusionCancers, Not Recruiting
- Phase I/II BTK Inhibitor Ibrutinib in Combo w/ MEDI4736 in Relapsed or Refractory Lymphomas, Not Recruiting
- Phase I/II JTX-2011+/-Nivolumab/Ipilimumab/Pembrolizumab in Advncd Refractory SolidTumorMalignancies, Not Recruiting
- Phase I/II of EDO-S101 in Advanced Solid Tumors, Not Recruiting
- Phase I/II SD-101 a TLR9 Agonist +/- Intravenous Checkpoint Blockade in Metastatic Uveal Melanoma, Not Recruiting
- Phase I/II Urelumab in Combo w/ Nivolumab in Advanced/Metastatic Solid Tumors & B Cell NHL, Not Recruiting
- Phase I/IIa PLX8394 in Patients with Advanced, Unresectable Solid Tumors, Not Recruiting
- Phase Ib/II Intratumoral SD-101 +Pembrolizumab in Metastatic Melanoma or Recurrent /Metastatic HNSCC, Not Recruiting
- Phase II Adjuvant vs NeoAdjuvant MK-3475 (Pembrolizumab) in Stage III-IV High-Risk Melanoma, Not Recruiting
- Phase II Capecitabine in Advanced or Recurrent Squamous Cell Carcinoma of the Skin, Not Recruiting
- Phase II Dasatinib for Unresectable Locally Advanced or Stage IV Mucosal, Acral and Solar Melanomas, Not Recruiting
- Phase II IMCgp100 vs Investigator Choice in HLA-A*0201 Positive Untreated Advanced Uveal Melanoma, Not Recruiting
- Phase II INCMGA00012 in Metastatic Merkel Cell Carcinoma, Not Recruiting
- Phase II MK-3475 in Advanced Merkel Cell Carcinoma (MCC), Not Recruiting
- Phase II Non-myeloablative Allogeneic Transplant Using TLI & ATG In Cutaneous T Cell Lymphoma, Not Recruiting
- Phase II of Three Treatment Regimens of SPAPE in Stage IA, IB or IIA Cutaneous T-Cell Lymphoma, Not Recruiting
- Phase II Pembrolizumab in Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC), Not Recruiting
- Phase II REGN2810 in Advanced Basal Cell Carcinoma, Not Recruiting
- Phase II/III Nivolumab&Ipilimumab +/-Sargramostim in Unresectable Unresectable Stage III/IV Melanoma, Not Recruiting
- Phase III (Atezolizumab vs Placebo) + Cobimetinib & Vemurafenib in Metastatic Melanoma, Not Recruiting
- Phase III Adjuvant Immunotherapy + Relatlimab & Nivolumab vs Nivolumab in Stage III-IV Melanoma, Not Recruiting
- Phase III Adjuvant MK-3475 (Pembrolizumab) vs SoC Observation in Resected Merkel Cell Carcinoma, Not Recruiting
- Phase III Cobimetinib+Atezolizumab vs Pembrolizumab in Previously Un-Tx BRAFV600 Wild-Type Melanoma , Not Recruiting
- Phase III High Dose Interferon or Ipilimumab vs MK-3475(Pembrolizumab) in HighRisk Resected Melanoma, Not Recruiting
- Phase III IMO-2125 + Ipilimumab vs Ipilimumab Alone in Anti-PD-1 Refractory Melanoma, Not Recruiting
- Phase III MEK162 vs Dacarbazine in Advanced Unresectable / Metastatic NRAS Mutation+ Melanoma, Not Recruiting
- Phase III Monoclonal Antibody KW-0761 (Mogamulizumab) Vs Vorinostat in Cutaneous T-Cell Lymphoma , Not Recruiting
- Phase III Nivolumab+Relatlimab Fixeddose Combo vs Nivolumab+Relatlimab Fixed-dose Combo in Melanoma, Not Recruiting
- Phase III NKTR-214 +Nivolumab vsNivolumab in Previously Untreated /Unresectable /Metastatic Melanoma, Not Recruiting
- Phase III PDR001+Dabrafenib+Trametinib vs Placebo+Dabrafenib+Trametinib in BRAF V600 Mutant Melanoma, Not Recruiting

- Phase III Vemurafenib (RO5185426) Adjuvant Tx in Surgically Resected Cutaneous BRAF-Mutant Melanoma, Not Recruiting
- Phase I KPT-9274 Dual Inhibitor of PAK4 & NAMPT in Advanced Solid Malignancies /Non-Hodgkins Lymphoma, Not Specified

Publications

PUBLICATIONS

- **Toward the Development of Functional Biomarker Assays: Analysis of Neoadjuvant Intralesional Oncolytic Virus Response in High-Risk Stage II Melanoma**
Kirane, A., Lee, D., Ahmad, M., Sharma, S., Serasanambati, M., Lowe, M., Applebee, C., Safrygina, E., Swetter, S., Reddy, S., Warner, A., Funchain, P., Wang, et al
SPRINGER.2024: S33-S34
- **ESC Cardio-Oncology Guidelines: A Triumph-But Are We Overscreening?** *JACC. CardioOncology*
Witteles, R. M., Reddy, S. A.
2023; 5 (1): 133-136
- **Intracranial Control With Combination BRAF and MEK Inhibitor Therapy in Patients With Metastatic Melanoma.** *Cureus*
Hui, C., Wu, Y. F., Liu, K., Sandhu, N., Blomain, E., Binkley, M. S., Gephart, M. H., Chang, S. D., Li, G. H., Reddy, S. A., Soltys, S. G., Pollom, E.
2022; 14 (11): e31838
- **Health Care Utilization and Costs in Systemic Therapies for Metastatic Melanoma from 2016 to 2020.** *The oncologist*
Qian, M. F., Betancourt, N. J., Pineda, A., Maloney, N. J., Nguyen, K. A., Reddy, S. A., Hall, E. T., Swetter, S. M., Zaba, L. C.
2022
- **Identification of Pathogenic Immune Cell Subsets Associated With Checkpoint Inhibitor-Induced Myocarditis.** *Circulation*
Zhu, H., Galdos, F. X., Lee, D., Waliyany, S., Vivian Huang, Y., Ryan, J., Dang, K., Neal, J. W., Wakelee, H. A., Reddy, S. A., Srinivas, S., Lin, L. L., Witteles, et al
2022: 101161CIRCULATIONAHA121056730
- **FOCUS phase 3 trial results: Percutaneous hepatic perfusion (PHP) with melphalan for patients with ocular melanoma liver metastases (PHP-OCM-301/301A).**
Zager, J. S., Orloff, M. M., Ferrucci, P., Glazer, E., Ejaz, A., Richtig, E., Ochsenreither, S., Lowe, M. C., Reddy, S. A., Beasley, G., Gesierich, A., Dummer, R., Arance, et al
LIPPINCOTT WILLIAMS & WILKINS.2022
- **Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology.** *Journal of the National Comprehensive Cancer Network : JNCCN*
Thompson, J. A., Schneider, B. J., Brahmer, J., Achufusi, A., Armand, P., Berkenstock, M. K., Bhatia, S., Budde, L. E., Chokshi, S., Davies, M., Elshoury, A., Gesthalter, Y., Hegde, et al
2022; 20 (4): 387-405
- **The complexity of carcinosarcoma.** *Oncology (Williston Park, N.Y.)*
Reddy, S.
1800; 35 (12): 814
- **Intracranial Response to Combination BRAF and MEK Inhibitor Therapy in Patients with Metastatic Melanoma**
Hui, C., Wu, Y., Liu, K., Sandhu, N., Blomain, E., Binkley, M., Gephart, M., Chang, S., Li, G., Reddy, S., Gibbs, I., Soltys, S., Pollom, et al
LIPPINCOTT WILLIAMS & WILKINS.2021: S48-S49
- **Use of a computer model and care coaches to increase advance care planning conversations for patients with metastatic cancer**
Gupta, D., Fardeen, T., Teuteberg, W., Seevaratnam, B., Asuncion, M., Alves, N., Rogers, B., Neal, J. W., Fan, A. C., Parikh, D., Patel, M. I., Shah, S., Srinivas, et al
LIPPINCOTT WILLIAMS & WILKINS.2021
- **Complete remission from intralesional talimogene laherparepvec for regionally advanced Merkel cell carcinoma in an immunocompromised solid organ transplant patient.** *JAAD case reports*
Hirotsu, K. E., Hua, V., Tran, A. T., Morris, L., Reddy, S. A., Kwong, B. Y., Zaba, L. C.
2021; 13: 144-146

- **Percutaneous hepatic perfusion (PHP) with melphalan for patients with ocular melanoma liver metastases: Preliminary results of FOCUS (PHP-OCM-301/301A) phase III trial.**
Zager, J. S., Orloff, M., Ferrucci, P., Glazer, E., Ejaz, A., Richtig, E., Ochsenreither, S., Lowe, M. C., Reddy, S. A., Beasley, G., Gesierich, A., Dummer, R., Arance, et al
LIPPINCOTT WILLIAMS & WILKINS.2021
- **Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma.** *Journal for immunotherapy of cancer*
Nghiem, P., Bhatia, S., Lipson, E. J., Sharfman, W. H., Kudchadkar, R. R., Brohl, A. S., Friedlander, P. A., Daud, A., Kluger, H. M., Reddy, S. A., Boulmay, B. C., Riker, A., Burgess, et al
2021; 9 (4)
- **Myocarditis Surveillance with High-Sensitivity Troponin I During Cancer Treatment with Immune Checkpoint Inhibitors.** *JACC. CardioOncology*
Waliy, S., Neal, J. W., Reddy, S., Wakelee, H., Shah, S. A., Srinivas, S., Padda, S. K., Fan, A. C., Colevas, A. D., Wu, S. M., Witteles, R. M., Zhu, H.
2021; 3 (1): 137–39
- **Liquid biopsy proteomics of uveal melanoma reveals biomarkers associated with metastatic risk.** *Molecular cancer*
Velez, G., Nguyen, H. V., Chemudupati, T., Ludwig, C. A., Toral, M., Reddy, S., Mruthyunjaya, P., Mahajan, V. B.
2021; 20 (1): 39
- **Prognostic value of bone marrow metabolism on pretreatment 18F-FDG PET/CT in patients with metastatic melanoma treated with anti-PD-1 therapy.** *Journal of nuclear medicine : official publication, Society of Nuclear Medicine*
Nakamoto, R., Zaba, L. C., Liang, T., Reddy, S. A., Davidzon, G., Aparici, C. M., Nguyen, J., Moradi, F., Iagaru, A., Franc, B. L.
2021
- **Immune Profiling and Causal Antigen Discovery in Mouse and Human Models of Immune Checkpoint Inhibitor-induced Myocarditis**
Zhu, H., Lee, D., Sarah, W., Galdos, F. X., D'Addabbo, J., Fowler, M. B., Reddy, S., Heather, W., Neal, J. W., Witteles, R., Maecker, H. T., Davis, M., Nguyen, et al
LIPPINCOTT WILLIAMS & WILKINS.2020
- **Imaging characteristics and diagnostic performance of F-18-FDG PET/CT for melanoma patients who demonstrate hyperprogressive disease when treated with immunotherapy**
Nakamoto, R., Zaba, L., Rosenberg, J., Reddy, S., Nobashi, T., Davidzon, G., Aparici, C., Nguyen, J., Moradi, F., Iagaru, A., Franc, B.
SOC NUCLEAR MEDICINE INC.2020
- **Prognostic value of volumetric PET parameters at early response evaluation in melanoma patients treated with immunotherapy**
Nakamoto, R., Zaba, L., Rosenberg, J., Reddy, S., Nobashi, T., Davidzon, G., Aparici, C., Nguyen, J., Moradi, F., Iagaru, A., Franc, B.
SOC NUCLEAR MEDICINE INC.2020
- **A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma.** *Clinical cancer research : an official journal of the American Association for Cancer Research*
Postow, M. A., Knox, S. J., Goldman, D. A., Elhanati, Y., Mavinkurve, V., Wong, P., Halpenny, D. F., Reddy, S. A., Vado, K. P., McCabe, D., Ramirez, K. A., Macri, M., Schwarzenberger, et al
2020
- **Durability of response in metastatic melanoma patients after combined treatment with radiation therapy and ipilimumab.** *Melanoma management*
Sodji, Q. H., Gutkin, P. M., Swetter, S. M., Reddy, S. A., Hiniker, S. M., Knox, S. J.
2020; 7 (1): MMT36
- **Economics of alternative dosing strategies for pembrolizumab and nivolumab at a single academic cancer center.** *Cancer medicine*
Hall, E., Zhang, J., Kim, E. J., Hwang, G., Chu, G., Bhatia, S., Reddy, S.
2020
- **Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase I/II trial.** *The Journal of experimental medicine*
Frank, M. J., Khodadoust, M. S., Czerwinski, D. K., Haabeth, O. A., Chu, M. P., Miklos, D. B., Advani, R. H., Alizadeh, A. A., Gupta, N. K., Maeda, L. S., Reddy, S. A., Laport, G. G., Meyer, et al
2020; 217 (9)

- **Intracranial Tumor Control Following Immune-Related Adverse Events and Discontinuation of Immunotherapy for Melanoma.** *World neurosurgery*
Zhang, M. n., Rodrigues, A. J., Bhambhani, H. P., Fatemi, P. n., Pollom, E. L., Gibbs, I. C., Thomas, R. P., Soltys, S. G., Hancock, S. L., Chang, S. D., Reddy, S. A., Gephart, M. H., Li, et al
2020
- **NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020.** *Journal of the National Comprehensive Cancer Network : JNCCN*
Thompson, J. A., Schneider, B. J., Brahmer, J., Andrews, S., Armand, P., Bhatia, S., Budde, L. E., Costa, L., Davies, M., Dunnington, D., Ernstoff, M. S., Frigault, M., Kaffenberger, et al
2020; 18 (3): 230–41
- **"Giant cell arteritis manifesting as retinal arterial occlusion and paracentral acute middle maculopathy in a patient on pembrolizumab for metastatic uveal melanoma".** *American journal of ophthalmology case reports*
Narala, R. n., Reddy, S. A., Mruthyunjaya, P. n.
2020; 20: 100891
- **Prognostic value of volumetric PET parameters at early response evaluation in melanoma patients treated with immunotherapy.** *European journal of nuclear medicine and molecular imaging*
Nakamoto, R. n., Zaba, L. C., Rosenberg, J. n., Reddy, S. A., Nobashi, T. W., Davidzon, G. n., Aparici, C. M., Nguyen, J. n., Moradi, F. n., Iagaru, A. n., Franc, B. L.
2020
- **A phase 1b, open-label, investigator-initiated, proof-of-concept study of pembrolizumab for advanced basal cell carcinomas**
Chang, A., Duy Tran, Cannon, J., Li, S., Jeng, M., Rieger, K., Reddy, S., Sarin, K., Colevas, D.
MOSBY-ELSEVIER.2019: AB8
- **Economic analysis of alternative pembrolizumab and nivolumab dosing strategies at an academic cancer center.**
Hall, E., Zhang, J., Kim, E., Hwang, G., Bhatia, S., Reddy, S. A.
AMER SOC CLINICAL ONCOLOGY.2019
- **Phase 1b/2, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced/metastatic melanoma resistant to anti-PD-1/PD-L1 therapy.**
Amin, A., Milhem, M. M., Long, G. V., Hoimes, C. J., Medina, T., Conry, R., Lao, C. D., Daniels, G. A., Reddy, S. A., Andtbacka, R., Barve, M. A., Shaheen, M. F., Tueting, et al
AMER SOC CLINICAL ONCOLOGY.2019
- **Management of Immunotherapy-Related Toxicities. Version 1.2019** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
Thompson, J. A., Schneider, B. J., Brahmer, J., Andrews, S., Armand, P., Bhatia, S., Budde, L. E., Costa, L., Davies, M., Dunnington, D., Ernstoff, M. S., Frigault, M., Hoffner, et al
2019; 17 (3): 255–88
- **Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
Nghiem, P., Bhatia, S., Lipson, E. J., Sharfman, W. H., Kudchadkar, R. R., Brohl, A. S., Friedlander, P. A., Daud, A., Kluger, H. M., Reddy, S. A., Boulmay, B. C., Riker, A. I., Burgess, et al
2019: JCO1801896
- **Predicting Response to Immunotherapy by Evaluating Tumors, Lymphoid Cell-Rich Organs, and Immune-Related Adverse Events Using FDG-PET/CT.** *Clinical nuclear medicine*
Nobashi, T., Baratto, L., Reddy, S. A., Srinivas, S., Toriihara, A., Hatami, N., Yohannan, T. K., Mitra, E.
2019
- **Complete Response of Metastatic Melanoma to Local Radiation and Immunotherapy: 6.5 Year Follow-Up.** *Cureus*
Gutkin, P. M., Hiniker, S. M., Swetter, S. M., Reddy, S. A., Knox, S. J.
2018; 10 (12): e3723
- **Pembrolizumab for advanced basal cell carcinoma: an investigator-initiated, proof-of-concept study.** *Journal of the American Academy of Dermatology*
Chang, A. L., Tran, D. C., Cannon, J. G., Li, S. n., Jeng, M. n., Patel, R. n., Van der Bokke, L. n., Pague, A. n., Brotherton, R. n., Rieger, K. E., Satpathy, A. T., Yost, K. E., Reddy, et al

2018

- **Phase I Trial: SABR and Ipilimumab-Letter.** *Clinical cancer research : an official journal of the American Association for Cancer Research*
Hiniker, S. M., Reddy, S. A., Swetter, S. M., Knox, S. J.
2017; 23 (1): 320
- **A Prospective Clinical Trial Combining Radiation Therapy With Systemic Immunotherapy in Metastatic Melanoma.** *International journal of radiation oncology, biology, physics*
Hiniker, S. M., Reddy, S. A., Maecker, H. T., Subrahmanyam, P. B., Rosenberg-Hasson, Y., Swetter, S. M., Saha, S., Shura, L., Knox, S. J.
2016; 96 (3): 578-588
- **Romidepsin for the treatment of relapsed/refractory cutaneous T-cell lymphoma (mycosis fungoides/Sézary syndrome): Use in a community setting.** *Critical reviews in oncology/hematology*
Reddy, S. A.
2016; 106: 99-107
- **PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma** *NEW ENGLAND JOURNAL OF MEDICINE*
Nghiem, P. T., Bhatia, S., Lipson, E. J., Kudchadkar, R. R., Miller, N. J., Annamalai, L., Berry, S., Chartash, E. K., Daud, A., Fling, S. P., Friedlander, P. A., Kluger, H. M., Kohrt, et al
2016; 374 (26): 2542-2552
- **Tumor DNA in cerebral spinal fluid reflects clinical course in a patient with melanoma leptomeningeal brain metastases** *JOURNAL OF NEURO-ONCOLOGY*
Li, Y., Pan, W., Connolly, I. D., Reddy, S., Nagpal, S., Quake, S., Gephart, M. H.
2016; 128 (1): 93-100
- **Toward rapid learning in cancer treatment selection: An analytical engine for practice-based clinical data.** *Journal of biomedical informatics*
Finlayson, S. G., Levy, M., Reddy, S., Rubin, D. L.
2016; 60: 104-113
- **Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project.** *Journal of clinical oncology*
Kim, Y. H., Tavallaee, M., Sundram, U., Salva, K. A., Wood, G. S., Li, S., Rozati, S., Nagpal, S., Krathen, M., Reddy, S., Hoppe, R. T., Nguyen-Lin, A., Weng, et al
2015; 33 (32): 3750-3758
- **Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project.** *Journal of clinical oncology*
Kim, Y. H., Tavallaee, M., Sundram, U., Salva, K. A., Wood, G. S., Li, S., Rozati, S., Nagpal, S., Krathen, M., Reddy, S., Hoppe, R. T., Nguyen-Lin, A., Weng, et al
2015; 33 (32): 3750-3758
- **Clinically significant responses achieved with romidepsin across disease compartments in patients with cutaneous T-cell lymphoma** *LEUKEMIA & LYMPHOMA*
Kim, E. J., Kim, Y. H., Rook, A. H., Lerner, A., Duvic, M., Reddy, S., Robak, T., Becker, J. C., Samtsov, A., McCulloch, W., Waksman, J., Whittaker, S.
2015; 56 (10): 2847-2854
- **Involution of eruptive melanocytic nevi on combination BRAF and MEK inhibitor therapy.** *JAMA dermatology*
Chen, F. W., Tseng, D., Reddy, S., Daud, A. I., Swetter, S. M.
2014; 150 (11): 1209-1212
- **Involution of Eruptive Melanocytic Nevi on Combination BRAF and MEK Inhibitor Therapy** *JAMA DERMATOLOGY*
Chen, F. W., Tseng, D., Reddy, S., Daud, A. I., Swetter, S. M.
2014; 150 (11): 1209-1212
- **Markedly improved overall survival in 10 consecutive patients with metastatic basal cell carcinoma** *BRITISH JOURNAL OF DERMATOLOGY*
Danial, C., Lingala, B., Balise, R., Oro, A. E., Reddy, S., Colevas, A., Chang, A. L.
2013; 169 (3): 673-676
- **Markedly improved overall survival in 10 consecutive patients with metastatic basal cell carcinoma.** *British journal of dermatology*
Danial, C., Lingala, B., Balise, R., Oro, A. E., Reddy, S., Colevas, A., Chang, A. L.

2013; 169 (3): 673-676

- **A Systemic Complete Response of Metastatic Melanoma to Local Radiation and Immunotherapy** *TRANSLATIONAL ONCOLOGY*
Hiniker, S. M., Chen, D. S., Reddy, S., Chang, D. T., Jones, J. C., Mollick, J. A., Swetter, S. M., Knox, S. J.
2012; 5 (6): 404-407
- **Final Results From a Multicenter, International, Pivotal Study of Romidepsin in Refractory Cutaneous T-Cell Lymphoma** *JOURNAL OF CLINICAL ONCOLOGY*
Whittaker, S. J., Demierre, M., Kim, E. J., Rook, A. H., Lerner, A., Duvic, M., Scarisbrick, J., Reddy, S., Robak, T., Becker, J. C., Samtsov, A., McCulloch, W., Kim, et al
2010; 28 (29): 4485-4491
- **A Phase II Study of SGN-30 in Cutaneous Anaplastic Large Cell Lymphoma and Related Lymphoproliferative Disorders** *CLINICAL CANCER RESEARCH*
Duvic, M., Reddy, S. A., Pinter-Brown, L., Korman, N. J., Zic, J., Kennedy, D. A., Lorenz, J., Sievers, E. L., Kim, Y. H.
2009; 15 (19): 6217-6224
- **Prognostic Factors in Primary Cutaneous Anaplastic Large Cell Lymphoma Characterization of Clinical Subset With Worse Outcome** *49th Annual Meeting of the American-Society-of-Hematology*
Woo, D. K., Jones, C. R., Vanoli-Storz, M. N., Kohler, S., Reddy, S., Advani, R., Hoppe, R. T., Kim, Y. H.
AMER MEDICAL ASSOC.2009: 667-74
- **Indolent primary cutaneous B-cell lymphoma: Experience using systemic rituximab** *JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY*
Morales, A. V., Advani, R., Horwitz, S. M., Riaz, N., Reddy, S., Hoppe, R. T., Kim, Y. H.
2008; 59 (6): 953-957
- **Plant-produced idiotype vaccines for the treatment of non-Hodgkin's lymphoma: Safety and immunogenicity in a phase I clinical study** *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA*
McCormick, A. A., Reddy, S., Reinl, S. J., Cameron, T. I., Czerwinski, D. K., Vojdani, F., Hanley, K. M., Garger, S. J., White, E. L., Novak, J., Barrett, J., Holtz, R. B., Tuse, et al
2008; 105 (29): 10131-10136
- **Molecular rescue of tumour-specific T cell receptor idiotype from T cell lymphomas** *BRITISH JOURNAL OF HAEMATOLOGY*
Reddy, S. A., Levy, R.
2004; 124 (5): 626-628
- **CD30(+) cutaneous lymphoproliferative disorders: The Stanford experience in lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma** *JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY*
Liu, H. L., Hoppe, R. T., Kohler, S., Harvell, J. D., Reddy, S., Kim, Y. H.
2003; 49 (6): 1049-1058
- **T cell antigen receptor vaccines for active therapy of T cell malignancies** *Conference on Basic and Clinical Relevant Biology of Cutaneous T Cell Lymphoma*
Reddy, S. A., Okada, C., Wong, C., Bahler, D., Levy, R.
NEW YORK ACAD SCIENCES.2001: 97-105
- **Favorable treatment outcome in non-Hodgkin's lymphoma patients with "poor" mobilization of peripheral blood progenitor cells** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
Stockerl-Goldstein, K. E., Reddy, S. A., Horning, S. J., Blume, K. G., Chao, N. J., Hu, W. W., JOHNSTON, L. J., Long, G. D., Strober, S., Wong, R. M., Feiner, R. H., Kohler, S., Negrin, et al
2000; 6 (5): 506-512